Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jan;59(2):282.
doi: 10.1111/apt.17798.

Editorial: The evolving paradigms and treatments for primary biliary cholangitis-Authors' reply

Marlyn J Mayo  1 , John M Vierling  2 , Christopher L Bowlus  3
Affiliations
Editorial

Editorial: The evolving paradigms and treatments for primary biliary cholangitis-Authors' reply

Marlyn J Mayo et al. Aliment Pharmacol Ther. 2024 Jan.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Vuppalanchi R, Kowdely K. Editorial: the evolving paradigms and treatments for primary biliary cholangitis. Aliment Pharmacol Ther. 2024;59:280-281.
    1. Mayo MJ, Vierling JM, Bowlus CL, Levy C, Hirschfield G, Neff GW, et al. Open-label, clinical trial extension: two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2024;59:186-200. https://doi.org/10.1111/apt.17755
    1. Harrison SA, Gunn NT, Khazanchi A, Guy CD, Brunt EM, Moussa S, et al. A 52-week multi-center double-blind randomized phase 2 study of seladelpar, a potent and selective peroxisome proliferator-activated receptor delta (PPAR-delta) agonist, in patients with nonalcoholic steatohepatitis (NASH). Hepatology. 2020;72(S1):1042A-1043A.
    1. Watkins PB, Kleiner DW, Bedossa P, Goodman Z, Kaplowitz N, Maddrey W, et al. An independent blinded review of suspected drug-induced liver injury (DILI) in nonalcoholic steatohepatitis (NASH) patients by a panel of pathologists and hepatologists: lessons learned from the Seladelpar hepatotoxicity review committee (SHRC). J Hepatol. 2021;75(S2):S593-S594.

MeSH terms

Grants and funding

LinkOut - more resources